Standard BioTools Q2 revenue up 47% to $27.7M; gross margins surge

STANDARD BIOTOOLS INC.

2023-Q2 EPS reported -$0.43 revenue$52,785,000

Revenue $27.7M (+47% YoY); GAAP gross margin 49.2% vs 23.6% YoY.
Non-GAAP gross margin 60.9% vs 40.2%; operating loss improved to ($17.4M) from ($38.6M).
Non-GAAP operating expenses down 25% to $25.2M; net loss ($17.0M) vs ($63.5M).
Non-GAAP adjusted EBITDA loss ($8.4M) vs ($26.2M); operating cash use down >70% to $8.5M.
Cash and equivalents $143.1M; launched Hyperion XTi Imaging System.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STANDARD BIOTOOLS INC. reported quarter ended June 30, 2023 results: revenue $27.7, net income ($17.0).

Period: quarter ended June 30, 2023
Revenue: $27.7
Net income: ($17.0)
Result: reported results

Exact text from the filing

Selected Financial Results (Numbers in millions, except percentages) Quarter Ended June 30, 2023 Quarter Ended June 30, 2022 Revenue $27.7 $18.8 (a) Gross margin 49.2% 23.6% Non-GAAP gross margin 60.9% 40.2% Operating expenses $31.1 $43.0 Non-GAAP operating expenses $25.2 $33.8 Operating loss ($17.4) ($38.6) Net loss ($17.0) ($63.5)

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001162194-23-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.